283498US0PCT Docket No.

MAIL STOP PCT

ÉS PATENT AND TRADEMARK OFFICE IN THE

IN RE APPLICATION OF:

Antoni TORRENS JOVER, et al.

SERIAL NO: -10/566,132

GAU:

FILED:

January 27, 2006

EXAMINER:

FOR:

ACTIVE SUBSTANCE COMBINATION COMPRISING A 2,5-DIHYDROXYBENZENESULFONIC

COMPOUND AND A POTASSIUM ION CHANNEL MODULATOR

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR ·

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

Tel. (703) 413-3000

Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

APR 2 7 2006

SHEET OF SERIAL NO. ATTY DOCKET NO. Form PTO 1449 (Modified) WA BEAR BOOK 10/566,132 283498US0PCT **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Antoni TORRENS JOVER, et al. FILING DATE **GROUP** January 27, 2006 **U.S. PATENT DOCUMENTS FILING DATE** SUB **EXAMINER** DOCUMENT **CLASS** DATE NAME INITIAL NUMBER **CLASS** IF APPROPRIATE AΑ AB AC AD ΑE AF AG AH ΑI AJ ΑK Αf AM ΑN **FOREIGN PATENT DOCUMENTS DOCUMENT** TRANSLATION DATE COUNTRY NUMBER YES NO 03 004097 01/16/03 NO AO WO (with English abstract) NO ΑP 10/16/97 WO (with English abstract) 97 37647 NO 0 477 819 04/01/92 EP AQ NO AR 2 201 888 05/03/74 FR AS ΑT ΑU ΑV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) ANGULO et al. "Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries", British Journal of Pharmacology, vol. 139, pages 854-862 ΑW SANZ et al. "In vitro effects of calcium dobesilate on the responsiveness of spontaneously diabetic rat aorta", Japanese Journal of Pharmacology, vol. 78, no. 3, pages 391-394, BASE DE DATOS CA en STN, AN 130:133918, English abstract AX only RUIZ et al. "Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta", British Journal of Pharmacology, vol. 121, no. 4, pages 711-716, BASE DE DATOS CA en STN, AN 127:117187, English abstract only 1997 SOBEY. "Potassium Channel Function in Vascular Disease", Arterioscler Thromb Vasc Biol, vol. 21, pages 28-38 ΑZ Additional References sheet(s) attached 2001

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner

Date Considered